ArticleInternational journal of cardiology. Heart & vasculature2026
Association between coronary vasomotor dysfunction and autoimmune disease in patients undergoing invasive coronary function testing.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune diseases (AD) are associated with increased cardiovascular risk, but their relationship with coronary vasomotor dysfunction (CVDys) in patients with angina with nonobstructive coronary arteries (ANOCA) remains unclear. Methods: We retrospectively analyzed 242 adults with ANOCA who underwent invasive coronary function testing. Patients were categorized by AD status, with systemic and organ-specific AD also evaluated separately. CVDys endotypes, including coronary microvascular dysfunction (CMD), vasospastic angina (VSA), and endothelial dysfunction, were compared using adjusted risk ratios. Clinical outcomes were assessed with time-to-event analyses. Results: Of 242 patients (74.8% female), 91 (37.6%) had AD. CVDys was common in both patients with and without AD (81.3% vs 80.8%; Conclusions: Autoimmune disease was not associated with higher CVDys prevalence or adverse cardiovascular outcomes in patients with ANOCA undergoing invasive CFT. Invasive testing identified diverse CVDys endotypes among patients with AD, supporting the utility of comprehensive phenotyping in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.